Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
memo - Magazine of European Medical Oncology

Open Access 30-04-2024 | short review

The molecular tumor board—a key element of precision oncology

Authors: Dr. Laura Boos, MHBA, Prof. Dr. Dr. Andreas Wicki

Published in: memo - Magazine of European Medical Oncology

Login to get access

Summary

Tumor profiling techniques have become an essential tool in cancer diagnostics creating an opportunity for individualized cancer care. Interpretation of results of molecular analyses and their integration into clinical practice, however, can be challenging. Molecular tumor boards play a key role in translating molecular findings into cancer treatment recommendations. In this short review we address important questions regarding the molecular tumor board set-up and highlight aspects of interest and challenges ahead.
Literature
1.
Mateo J, Chakravarty D, Dienstmann R, et al. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Ann Oncol. 2018;1;29(9):1895–902. Sep.CrossRef
2.
Tamborero D, Dienstmann R, Rachid MH, et al. The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology. Nat Cancer. 2022;3(2):251–61. Feb.CrossRefPubMedPubMedCentral
3.
Hoefflin R, Lazarou A, Hess ME, et al. Transitioning the Molecular Tumor Board from Proof of Concept to Clinical Routine: A German Single-Center Analysis. Cancers (basel). 2021;8;13(5):1151. Mar.CrossRefPubMed
4.
Kato S, Kim KH, Lim HJ, et al. Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N‑of-One strategy. Nat Commun. 2020;2;11(1):4965. Oct.CrossRef
5.
Rieke DT, Lamping M, Schuh M, et al. Comparison of Treatment Recommendations by Molecular Tumor Boards Worldwide. Jco Precis Oncol. 2018;2:1–14. Nov.CrossRefPubMed
6.
Schwaederle M, Parker BA, Schwab RB, et al. Molecular tumor board: the University of California-San Diego Moores Cancer Center experience. Oncologist. 2014;19(6):631–6. Jun.CrossRefPubMedPubMedCentral
7.
Zehir A, Benayed R, Shah RH, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med. 2017;23(6):703–13. Jun.CrossRefPubMedPubMedCentral
8.
Wahida A, Buschhorn L, Fröhling S, et al. The coming decade in precision oncology: six riddles. Nat Rev Cancer. 2023;23(1):43–54. Jan.CrossRefPubMed
9.
Irmisch A, Bonilla X, Chevrier S, et al. The Tumor Profiler Study: integrated, multi-omic, functional tumor profiling for clinical decision support. Cancer Cell. 2021;8;39(3):288–93. Mar.CrossRef
Metadata
Title
The molecular tumor board—a key element of precision oncology
Authors
Dr. Laura Boos, MHBA
Prof. Dr. Dr. Andreas Wicki
Publication date
30-04-2024
Publisher
Springer Vienna
Published in
memo - Magazine of European Medical Oncology
Print ISSN: 1865-5041
Electronic ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-024-00977-7
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits